Unique ID issued by UMIN | UMIN000000852 |
---|---|
Receipt number | R000001023 |
Scientific Title | Clinical study of alpha-GalactosylCeramide-pulsed dendritic cells and natural killer T (NKT) cells in patients with operable recurrent head and neck cancer |
Date of disclosure of the study information | 2008/06/30 |
Last modified on | 2012/11/29 14:28:29 |
Clinical study of alpha-GalactosylCeramide-pulsed dendritic cells and natural killer T (NKT) cells in patients with operable recurrent head and neck cancer
Clinical study of alpha-GalactosylCeramide-pulsed dendritic cells and natural killer T (NKT) cells in patients with operable recurrent head and neck cancer
Clinical study of alpha-GalactosylCeramide-pulsed dendritic cells and natural killer T (NKT) cells in patients with operable recurrent head and neck cancer
Clinical study of alpha-GalactosylCeramide-pulsed dendritic cells and natural killer T (NKT) cells in patients with operable recurrent head and neck cancer
Japan |
Head and neck squamous cell carcinoma
Oto-rhino-laryngology |
Malignancy
NO
The feasibility of alpha-GalactosylCeramide-pulsed dendritic cell and natural killer T (NKT) cell immunotherapy in patients with head and neck squamous cell carcinoma are examined. The clinical effects and immunological responses, safety are also investigated.
Efficacy
Exploratory
Explanatory
Phase II
Clinical responses
Histopathological decisions of clinical responses, NKT cell specific immunological responses in the tissue and peripheral blood, Frequency of adverse events, Disease free survivals
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine | Maneuver |
Sub-mucosal injections of alpha-GalactosylCeramide pulsed DCs are performed on day 7, and activated NKT cells is infused intra-arterially on day 14 after the entry.
20 | years-old | <= |
80 | years-old | >= |
Male and Female
Operable recurrent head and neck squamous cell carcinoma patients who have measurable lesion; Patients whose life-expectancy is more than 6 months; Performance status 0-1; Normal bone marrow, liver and renal functions; NKT cells are detected at least 10 cells in 1 mL of peripheral blood.
Patients who have: been treated with previous therapy of at least 4 weeks; uncontrolled diabetes mellitus, pulmonary fibrosis, and/or infection; a history of hepatitis; a positive response for hepatitis B surface antigen, or human immunodeficiency virus (HIV), hepatitis C virus, or human T-lymphotrophic virus antibodies; serious cardiac disease; recieived concurrent corticosteroid therapy; pregnancy or lactation; autoimmune diseases; been judged to be inappropriate to participate in this study by principle investigator or co-investigator
13
1st name | |
Middle name | |
Last name | Yoshitaka Okamoto |
Graduate School of Medicine, Chiba University
Department of Otorhinolaryngology, Head and Neck Surgery
1-8-1 Inohana, Chuo-ku, Chiba, Japan
043-226-2137
1st name | |
Middle name | |
Last name | Shigetoshi Horiguchi |
Graduate School of Medicine, Chiba University
Department of Otorhinolaryngology, Head and Neck Surgery
1-8-1 Inohana, Chuo-ku, Chiba, Japan
043-226-2137
Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University
The Ministry of Education, Culture, Sports, Science and Technology
Japan
NO
2008 | Year | 06 | Month | 30 | Day |
Unpublished
Completed
2007 | Year | 09 | Month | 12 | Day |
2007 | Year | 11 | Month | 01 | Day |
2010 | Year | 03 | Month | 01 | Day |
2012 | Year | 11 | Month | 29 | Day |
2012 | Year | 11 | Month | 29 | Day |
2012 | Year | 11 | Month | 29 | Day |
2007 | Year | 10 | Month | 16 | Day |
2012 | Year | 11 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001023